
GLP-1 obesity drugs linked to lower addiction risk in a massive VA study
A large observational study of electronic health records from over 600,000 US veterans found that GLP-1 drugs used for obesity and type 2 diabetes were associated with reduced risk of developing substance-use disorders and, among those with addiction, about a 50% lower risk of death from substance abuse. Among GLP-1 users with no prior addiction, three-year risks were 18% lower for alcohol, 14% lower for cannabis, 20% lower for cocaine, 20% lower for nicotine, and 25% lower for opioids compared with users of another diabetes medication, though randomized trials are needed to establish causality.












